NCT04321330View on ClinicalTrials.gov

A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

July 16, 2023

Study Completion Date

June 3, 2024

Conditions
Carcinoma, Thymic
Interventions
DRUG

Atezolizumab

Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.

Trial Locations (10)

200000

Shanghai Chest Hospital, Shanghai

266042

The affiliated hospital of Qingdao university, Qingdao

300060

Tianjin Cancer Hospital, Tianjin

310003

The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou

350001

Fujian Medical University Union Hospital, Fuzhou

400010

The Second Affiliated Hospital, Chongqing Medical University, Chongqing

450008

Henan Cancer Hospital, Zhengzhou

510120

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

610041

Sichuan Cancer Hospital, Chengdu

West China Hospital, Sichuan University; Department of Breast, Chengdu

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04321330 - A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma | Biotech Hunter | Biotech Hunter